


| Form PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 018733-1066 | | SERIAL NO. <u>10/02, 211</u> Unassigned | |
|---|-----|--|--------|-----------------------------------|------------|---|----------------------------------|
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | | | APPLICANT Milton D. GOLDENBERG | | GROUP ART UNIT <u>1644</u> Unassigned | |
| | | | | FILING DATE 12/05/2001 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | REF | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
| <u>C.C.</u> | A1 | 4,859,449 | 8/1989 | MATTES | <u>424</u> | <u>9</u> | |
| <u>I</u> | A2 | 4,735,210 | 4/1988 | GOLDENBERG | <u>128</u> | <u>654</u> | |
| <u>I</u> | A3 | 4,732,864 | 3/1988 | TOLMAN | <u>426</u> | <u>547</u> | |
| <u>I</u> | A4 | 4,444,744 | 4/1984 | GOLDENBERG | <u>424</u> | <u>1</u> | |
| <u>I</u> | A5 | 4,348,376 | 9/1982 | GOLDENBERG | <u>424</u> | <u>1</u> | |
| <u>C.C.</u> | A6 | 4,036,945 | 7/1977 | HABER | <u>424</u> | <u>1</u> | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | REF | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
| <u>C.C.</u> | A7 | 0 330 201 | 8/1989 | EUROPE | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| <u>C.C.</u> | A8 | BALDWIN et al., "Monoclonal Antibodies in Cancer Treatment," <i>Lancet</i> Vol. 1:8481, pp. 603-605 (1986). | | | | | |
| <u>C.C.</u> | A9 | RESKE et al., "Radioimmunoimaging for Diagnosis of Bone Marrow Involvement in Breast Cancer and Malignant Lymphoma," <i>Lancet</i> , Vol. 1, No. 8633, pp. 299-301 (1989). | | | | | |
| <u>C.C.</u> | A10 | DUNCKER et al., "Radioimmune Imaging of Bone Marrow in Patients with Suspected Bone Metastases From Primary Breast Cancer," <i>J. of Nuclear Medicine</i> , Vol. 31, No. 9, pp. 1450-1455 (1990). | | | | | |
| <u>C.C.</u> | A11 | RESKE et al., Nachweis des Knochenmarkbefalls beim Mammakarzinom und bei malignen Lymphomen durch Immunszintigraphie des hämatopoetischen Knochenmarks," <i>Rofo Fortschr. Geb. Rontgenstr. Neuen Bildgebenden Verfahren</i> , Vol. 152, No. 1, pp. 60-66 (1990). <u>abstract only</u> | | | | | |
| <u>C.C.</u> | A12 | SHARKEY et al., "Murine Monoclonal Antibodies Against Carcinoembryonic Antigen" Immunological, Pharmacokinetic, and Targeting Properties in Humans," <i>Cancer Research</i> , Vol. 50, No. 9, pp. 2823-2831 (1990). | | | | | |
| <u>C.C.</u> | A13 | DELAND et al., "Axiliary Lymphoscintigraphy by Radioimmunodetection of Carcinoembryonic Antigen in Breast Cancer," <i>J. of Nuclear Medicine</i> , Vol. 20, No. 12, pp. 1243-1250 (1979). | | | | | |
| <u>C.C.</u> | A14 | SIMPSON et al., "The Use of Monoclonal Antibody B72.3 in the Management of Gynecologic Malignancies," <i>Yale Journal of Biological Medicine</i> , Vol. 61, No. 4, pp. 351-366 (1988). | | | | | |
| EXAMINER <u>h ef</u> | | | | DATE CONSIDERED <u>8/11/06</u> | | | |
| * EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant. | | | | | | | |

BEST AVAILABLE COPY

| Form PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 018733-1066 | | SERIAL NO. <u>10/002,211</u> Unassigned | | |
|---|-----|---|------|-----------------------------------|-------|---|----------------------------------|----|
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | | | APPLICANT Milton D. GOLDENBERG | | | | |
| | | | | FILING DATE 12/05/2001 | | GROUP ART UNIT <u>1644</u> Unassigned | | |
| U.S. PATENT DOCUMENTS | | | | | | | | |
| EXAMINER INITIAL | REF | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | |
| | REF | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION | |
| | | | | | | | YES | NO |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | |
| C.C. | A15 | COLCHER et al., "Complementation of Intracavitary and Intravenous Administration of a Monoclonal Antibody (B72.3) in Patients with Carcinoma," <i>Cancer Research</i> , Vol. 47, No. 15, pp 4218-4224 (1987)/ | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| EXAMINER | | DATE CONSIDERED | | | | | | |
|  | | <u>8/1/06</u> | | | | | | |
| * EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant. | | | | | | | | |

BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information if it does not display a valid OMB number.

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: August 27, 2002

(use as many sheets as necessary)

Sheet

1

of

2

Application Number

10/002,211

Filing Date

12/05/2001

First Named Inventor

Milton D. GOLDENBERG

Group Art Unit

~~3763~~ 1644

Examiner Name

~~Unassigned~~ Chun Crowder

Attorney Docket Number

018733-1066

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

BEST AVAILABLE COPY

| | | | |
|-----------------------|---|--------------------|---------|
| Examiner Signature |  | Date Considered | 7/31/06 |
|-----------------------|---|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

2. Understand the Situation. This form is self-administered by the individual. Time will vary depending upon the nature of the individual's needs. It is recommended that

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


| | | | |
|--|---|--------------------------|----------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 27, 2002 (use as many sheets as necessary) | | Application Number | 10/002,211 |
| | | Filing Date | 12/05/2001 |
| | | First Named Inventor | Milton D. GOLDENBERG |
| | | Group Art Unit | 3763 |
| | | Examiner Name | Unassigned |
| Sheet | 2 | of | 2 |
| | | Attorney Docket Number | 018733-1066 |

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---|--------------------------|--|----------------|
|  | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |



 RECEIVED
 AUG 28 2002
 TECHNOLOGY CENTER R3700

BEST AVAILABLE COPY

| | | | |
|-----------------------|---|--------------------|---------|
| Examiner Signature |  | Date Considered | 7/31/06 |
|-----------------------|---|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete If Known

Application Number 10/002,211
 Filing Date 12/05/2001
 First Named Inventor David M. GOLDENBERG
 Group Art Unit 3763 1644
 Examiner Name Unassigned CHUN CROWDER
 Attorney Docket Number 018733-1066

FEB 09 2004

Sheet

1

of

2

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| | | Number | Kind Code ² (if known) | | | |
| C.C. | B1 | 4,036,945 | A | HABER | 07-19-1977 | |
| | B2 | 4,331,647 | A | GOLDENBERG | 05-25-1982 | |
| | B3 | 4,444,744 | A | GOLDENBERG | 04-24-1984 | |
| | B4 | 4,735,210 | A | GOLDENBERG | 04-05-1988 | |
| | B5 | 5,101,827 | A | GOLDENBERG | 04-07-1992 | |
| | B6 | 5,144,007 | A | PFAHL | 09-01-1992 | |
| C.C. | B7 | 5,152,980 | A | STROM et al. | 10-06-1992 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|--|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | B8 | EP | 0 217 992 | A | BETH ISRAEL HOSPITAL | 04-15-1987 | | |
| | B9 | EP | 0 274 394 | A | ONCOGEN | 07-13-1988 | | |
| | B10 | EP | 0 330 201 | A | NEORX CORPORATION | 08-30-1989 | | |
| | B11 | WO | 83/04313 | A | UNIV CALIFORNIA | 12-08-1983 | | |
| | B12 | WO | 89/07601 | A | TAN KIM SZE | 08-24-1989 | | |
| | B13 | WO | 91/16069 | A | US HEALTH | 10-31-1991 | | |
| | B14 | WO | 93/13805 | A | BAGSHAW | 07-22-1993 | | |
| | B15 | WO | 94/10202 | A | GENENTECH INC. | 05-11-1994 | | |

BEST AVAILABLE COPY

Examiner Signature

[Signature]

Date Considered

8/1/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|---------------------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |
| | | Application Number | 10/002,211 |
| (use as many sheets as necessary) | | Filing Date | 12/05/2001 |
| | | First Named Inventor | David M. GOLDENBERG |
| | | Group Art Unit | 3783 1640 |
| | | Examiner Name | Unassigned OKW CROWDER FEB 15 2004 |
| Sheet | 2 | of | 2 |
| | | Attorney Docket Number | 018733-1066 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | B16 | BOSSLET et al., "Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carcinoembryonic antigen (CEA)," <u>International Journal of Cancer - Journal International Du Cancer</u> , July 15, 1985, pp. 75-84, Vol. 36, No. 1 | |
| | B17 | DELAND et al., "Axillary lymphoscintigraphy by radioimmunoassay of carcinoembryonic antigen in breast cancer," <u>Journal of Nuclear Medicine</u> , 1979, pp. 1243-1250, Vol. 20, No. 12 | |
| | B18 | DILHUYDY et al., "Three-dimensional imaging of dual isotope data-sets in a case of acute myocardial infarction," <u>British Journal of Radiology</u> 1992 United Kingdom, March 1992, pp. 273-278, Vol. 65, No. 771 | |
| | B19 | DUNCKER et al., "Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer," <u>J. Nucl. Med.</u> , 1990, pp. 1450-1455, Vol. 31, No. 9 | |
| | B20 | MASUJIMA et al., "Biological component microanalysis by laser photoacoustic imaging immunoassay," <u>Chemical and Pharmaceutical Bulletin (Tokyo)</u> , 1989, pp. 1123-1125, Vol. 37, No. 4 | |
| | B21 | RESKE et al., "Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma," <u>Lancet</u> , 1989, pp. 299-301, Vol. 1, No. 8633 | |
| | B22 | SHARKEY et al., "Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic and targeting properties in humans," <u>Cancer Research</u> , 1990, pp. 2823-2831, Vol. 50, No. 9 | |
| | B23 | SIEGLE et al., "Development of a model using polypeptide antibodies for scintigraphy of the pancreas," <u>Investigative Radiology</u> , September 1980, pp. 457-461, Vol. 15, No. 5 | |
| | B24 | SIGNORE et al., "A radiopharmaceutical for imaging areas of lymphocytic infiltration: Iodine-123 interleukin-2: Labelling procedure and animal studies," <u>Nuclear Medicine Communications</u> , October 1992, pp. 713-722, Vol. 13, No. 10 | |
| | B25 | SIGNORE et al., "The in vivo visualization of insulinitis. A new marker of prediabetes," <u>Advances in Experimental Medicine and Biology</u> , 1988, pp. 119-125, Vol. 246 | |
| | B26 | TAKEDA et al., "Radioimmunolocalization of the monoclonal antibody J28 in early transformation stages in N-nitrosobis(2-hydroxypropyl)amine-induced pancreatic tumors in the Syrian golden hamster," <u>Journal of Cancer Research and Clinical Oncology</u> , 1992, pp. 377-385, Vol. 118, No. 5 | |
| | B27 | VOLPINI et al., "Diagnosis of acute myocardial infarction by indium-111 antimyosin antibodies and correlation with the traditional techniques for the evaluation of extent and localization," <u>The American Journal of Cardiology</u> , January 1, 1989, pp. 7-13, Vol. 63, No. 1 | |

BEST AVAILABLE COPY

| | | | |
|--------------------|-------------------|-----------------|--------|
| Examiner Signature | <i>C</i> <i>Q</i> | Date Considered | 8/2/06 |
|--------------------|-------------------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.